Newly diagnosed prostate cancer patients have multiple standard-of-care treatment options available, but many are not fully informed of their choices. A study led by researchers at The University of Texas MD Anderson Cancer Center found men who seek treatment at a multidisciplinary (MultiD) prostate cancer clinic are more likely to be advised about treatment choices and to receive care that complies with evidence-based treatment guidelines...
The University of Texas MD Anderson Cancer Center marks the 10th year of A Conversation With a Living Legend® in San Antonio with a luncheon...
Prostate cancer that spreads to the bone triggers the destruction of bone tissue that, in turn, thwarts the effectiveness of immune checkpoint...
Researchers from The University of Texas MD Anderson Cancer Center reported that secondary tumor-reduction, or cytoreduction, surgery followed by chemotherapy did not result in longer survival than chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancer.
The Phase III Gynecologic Oncology Group (GOG)-0213 trial results were published today in the New England Journal of Medicine. Early results from...
Kim Carstens, B.S.N., R.N., O.C.N., is the recipient of the 2019 Brown Foundation Award for Excellence in Oncology Nursing at The University...
The University of Texas MD Anderson Cancer Center, Artios Pharma Limited and ShangPharma Innovation today announce the in-licensing by Artios...
The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited today announced an exclusive license agreement...
For nearly 80 years, The University of Texas MD Anderson Cancer Center has been a global leader in the fight to end cancer. Our patients trust...